Positron emission tomography experience with 2-[ 18F]fluoro-3-(2(s)-azetidinylmethoxy)pyridine (2-[ 18F]fa) in the living human brain of smokers with paranoid schizophrenia

Synapse

Volumn 66, Issue 4, 2012, Pages 352-368

  Brašić, James Robert ^a   Cascella, Nicola ^a   Kumar, Anil ^a   Zhou, Yun ^a   Hilton, John ^a   Raymont, Vanessa ^a   Crabb, Andrew ^a   Guevara, Maria Rita ^a   Horti, Andrew G ^a   Wong, Dean Foster ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Kruskal Wallis H Statistic; Nicotinic acetylcholine receptor; Rank sum tests

Indexed keywords

2 FLUORO 3 (2 AZETIDINYLMETHOXY)PYRIDINE F 18; NICOTINIC RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOPSY; BINDING AFFINITY; BRAIN CORTEX; CAUDATE NUCLEUS; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; HYPOTHESIS; KRUSKAL WALLIS TEST; MALE; PARANOID SCHIZOPHRENIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; THALAMUS; TOBACCO DEPENDENCE;

ADULT; AZETIDINES; BRAIN; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, NICOTINIC; SCHIZOPHRENIA, PARANOID; SMOKING; YOUNG ADULT;

EID: 84856388179     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21520     Document Type: Article

References (83)

1. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV) Washington, DC: American Psychiatric Association.
2. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders, 4th ed., Text Revision (DSM-IV-TR™). Washington, DC: American Psychiatric Association.
3. Andreasen NC. 1984a. The schedule for the assessment of negative symptoms (SANS). Iowa City, Iowa: The University of Iowa.
4. Andreasen NC. 1984b. The schedule for the assessment of positive symptoms (SAPS). Iowa City, Iowa: The University of Iowa.
5. Ashburner J, Friston K. 1997. Multimodal image coregistration and partitioning-A unified framework. NeuroImage 6: 209-217.
6. Ashburner J, Neelin P, Collins DL, Evans A, Friston K. 1997. Incorporating prior knowledge into image registration. NeuroImage 6: 344-352.
7. Balfour DJK, Fagerström KO. 1996. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 72: 51-81.
8. Barnes TRE. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
9. Blacker D. 2009. Psychiatric rating scales. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan and Sadock's comprehensive textbook of psychiatry, 9th ed. Volume 1. Philadelphia: Lippincott Williams & Wilkins. p 1032-1059.
10. Brašić JR. 2003a. Documentation of demographic data. Psychol Rep 93: 151-152.
11. Brašić JR. 2003b. Treatment of movement disorders in autism spectrum disorders. In: Hollander E, editor. Autism spectrum disorders. Volume 24 of the Medical Psychiatry Series. ISBN 0-8247-0715-X New York: Marcel Dekker. p 273-346.
12. Brašić JR. 2004. Documentation of ethnicity. Psychol Rep 95: 859-861.
13. Brasić JR, Barnett JY, Sheitman BB, Lafargue RT, Kowalik S, Kaplan D, Tsaltas MO, Ahmad R, Nadrich RH, Mendonça MF. 1998. Behavioral effects of clomipramine on prepubertal boys with autistic disorder and severe mental retardation. CNS Spectrums: Int J Neuropsychiatric Med 3(10): 39-46.
14. Brasic JR, Bronson B, Chun TT. 2010a. Tardive Dyskinesia. eMedicine from WebMD. Updated January 21, 2010. Available at: .
15. 18F]FA) in the living human brain of smokers and nonsmokers. J Nucl Med 51 ( Supplement 2): 1828. [abstract].
16. Brašić JR, Rohde CA, Maris MA, Wong DF. 2003. Sample size determination for studies of Rett syndrome and other rare conditions. 4th Annual Rett Syndrome Symposium, Rett Syndrome Research Foundation, Baltimore, Maryland, June 23-25, 2003:46. [abstract]
17. Brasic JR, Wong DF. 2011. PET scanning in autism spectrum disorders. eMedicine from WebMD. Updated June 7, 2011.
18. th Annual Rett Syndrome Symposium, June 28-30, 2004, Inn at the Colonnade, Baltimore, Maryland, Rett Syndrome Research Foundation (RSRF), Cincinnati, Ohio page 2004; 44. [abstract]
19. 123I]IA) in the living human brain of smokers and nonsmokers. Synapse 63: 339-358.
20. Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM, Marks MJ, Collins AC, Leonard S. 2000. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23: 351-364.
21. 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 63: 907-915.
22. Campbell M. 1985. The timed stereotypies rating scale. Psychopharmacol Bull 21: 1082.
23. Chun TT, Brašić JR, Morgan RH. 2002. Is research on human beings with Rett syndrome ethical? 3rd Annual Rett Syndrome Symposium, Rett Syndrome Research Foundation, Baltimore, Maryland, June 17-19, 2002: 30. [abstract]
24. Denckla MB. 1985. Revised neurological examination for subtle signs (1985). Psychopharmacol Bull 21: 773-800.
25. Dominguez RA, Jacobson AF, de la Gandara J, Goldstein BJ, Steinbock RM. 1989. Drug response asssessed by the Modified Maudsley Obsessive-Compulsive Inventory. Psychopharmacol Bull 25: 215-218.
26. Dursun SM, Reveley MA. 1997. Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome: An open study. Psychol Med 27: 483-487.
27. Esterlis I, Cosgrove KP, Batis JC, Bois F, Stiklus SM, Perkins E, Seibyl JP, Carson RE, Staley JK. 2010. Quantification of smoking-induced occupancy of β2-nicotinic acetylcholine receptors: Estimation of nondisplaceable binding. J Nucl Med 51: 1226-1233.
28. First MB, Spitzer RL, Gibbon M, Williams JBW. 1997. Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press.
29. Folstein MF, Folstein SE, McHugh PR. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
30. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. 1989a. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 46: 1012-1016.
31. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. 1989b. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46: 1006-1011.
32. Guy W. 1976. ECDEU assessment manual for psychopharmacology, revised, 1976. (DHEW Publ. No. (ADM) 76-338) Washington, DC: United States Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration. p 218-222, 534-537.
33. Haut MW, Kuwabara H, Leach S, Arias RG. 2000a. Neural activation during performance of number-letter sequencing. Appl Neuropsychol 7: 237-242.
34. Haut MW, Kuwabara H, Leach S, Callahan T. 2000b. Age-related changes in neural activation during working memory performance. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 7: 119-129.
35. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. 2000. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol 27: 627-630.
36. Horti AG, Wong DF. 2009. Clinical perspective and recent development of PET radioligands for imaging cerebral nicotinic acetylcholine receptors. PET Clin 4: 89-100.
37. Horti AG, Gao Y, Kuwabara H, Dannals RF. 2010. Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci 86: 575-584.
38. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE. 2007. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
39. Kawakami N, Takatsuka N, Inaba S, Shimizu H. 1999. Developmental [sic] of screening questionnaire for tobacco/nicotine dependence according to ICD-10, DSM-III-R, and DSM-IV. Addict Behav 24: 155-166.
40. Kendziorra K, Wolf H, Meyer PM, Barthel H, Hesse S, Becker GA, Luthardt J, Schildan A, Patt M, Sorger D, Seese A, Gertz H-J, Sabri O. 2011. Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging 38: 515-525.
41. Kimes AS, Horti AG, London ED, Chefer SI, Contoreggi C, Ernst M, Friello P, Koren AO, Kurian V, Matochik JA, Pavlova O, Vaupel DB, Mukhin AG. 2003. 2-[18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J 17: 1331-1333.
42. Lafargue T, Brasic J. 2000. Neurodevelopmental hypothesis of schizophrenia: A central sensory disturbance. Med Hypotheses 55: 314-318.
43. Leckman JF, Towbin KE, Ort SI, Cohen DJ. 1988. Clinical assessment of tic disorder severity. In: Cohen DJ, Bruun RD, Leckman JF, editors. Tourette's syndrome and tic disorders. New York: Wiley. p 55-78.
44. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ. 1989. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28: 566-573.
45. 18F]Fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine. Molecular imaging and contrast agent database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2010.
46. Marder SR. 1995. Psychiatric rating scales. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry/VI, 6th ed. Volume 1. Baltimore: Williams & Wilkins. p 619-635.
47. Marks IM. 1986. Behavioural Psychotherapy: Maudsley Pocket Book of Clinical Management. Bristol: Wright. p 49.
48. McMahon RP, Kelly DL, Kreyenbuhl J, Kirkpatrick B, Love RC, Conley RR. 2002. Novel factor-based symptom scores in treatment resistant schizophrenia: Implications for clinical trials. Neuropsychopharmacology 26: 537-545.
49. Meyer PM, Strecker K, Kendziorra K, Becker G, Hesse S, Woelpl D, Hensel A, Patt M, Sorger D, Wegner F, Lobsien D, Barthel H, Brust P, Gertz HJ, Sabri O, Schwarz J. 2009. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 66: 866-877.
50. National Institute of Mental Health, Alcohol Drug Abuse, and Mental Health Administration, Public Health Service, Department of Health, Education and Welfare. 1988. Abnormal Involuntary Movement Scale (AIMS). Psychopharmacol Bull 24: 781-783.
51. 18F]Fluoro-A-85380 in human PET imaging studies. Nucl Med Biol 32: 869-874.
52. Overall JE, Gorham DR. 1962. The brief psychiatric rating scale. Psychol Rep 10: 799-812.
53. Pato MT, Pato CN. 1991. Psychometrics in obsessive-compulsive disorder. In: Zohar J, Insel T, Rasmussen S, editors. The psychobiology of obsessive-compulsive disorder. New York: Springer. p 87-88.
54. 2 nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioning. Neurosci Lett 415: 97-101.
55. Rustin TA. (August 1, 2000). Assessing nicotine dependence. American Family Physician. 62:579-584. Available at: .
56. Sachdev P. 1994. A rating scale for acute drug-induced akathisia: Development, reliability, and validity. Biol Psychiatry 35: 263-271.
57. Sanberg PR, Silver AA, Shytle RD, Philipp MK, Cahill DW, Fogelson HM, McConville BJ. 1997. Nicotine for the treatment of Tourette's syndrome. Pharmacol Ther 74: 21-25.
58. 18F]F-A-85380). Appl Radiat Isot 65: 1244-1248.
59. Shumway DA, Pavlova OA, Mukhin AG. 2007. A simplified method for the measurement of nonmetabolized 2-[18F]F-A-85380 in blood plasma using solid-phase extraction. Nucl Med Biol 34: 221-228.
60. Simpson GM, Lee JH, Zoubok B, Gardos G. 1979. A rating scale for tardive dyskinesia. Psychopharmacology (Berl) 64: 171-179.
61. 18F]fluoro-A-85380 and its metabolites in human blood during PET investigation: A methodological study. Nucl Med Biol 34: 331-342.
62. Sossi V, de Jong HWAM, Barker WC, Bloomfield P, Burbar Z, Camborde ML, Comtat C, Eriksson LA, Houle S, Keator D, Knoss C, Krais R, Lammertsma AA, Rahmim A, Sibomana M, Teras M, Thompson CJ, Trebossen R, Votaw J, Walker M, Wienhard K, Wong DF. 2005. The second generation HRRT-A multi-centre scanner performance investigation. 2005 IEEE Nuclear Science Symposium Conference Record, Volumes 1-5, p. 2195-2199.
63. StataCorp. 2003. Stata Statistical Software: Release 8.0. College Station, TX: Stata Corporation.
64. Tandon R, Keshavan MS, Nasrallah HA. 2008. Schizophrenia, "just the facts" what we know in 2008. II. Epidemiology and etiology. Schizophr Res 102: 1-18.
65. United States Census Bureau, Population Division. 2010. National and State Population Estimates. Annual Population Estimates 2000 to 2009. (NST-EST2009-01): Available at:
66. Ward MF, Wender PH, Reimherr FW. 1993. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 150: 885-890.
67. Wender PH. 1995. Attention-deficit hyperactivity disorder in adults. New York, NY: Oxford University Press.
68. Wender PH, Wolf LE, Wasserstein J. 2001. Adults with ADHD: An overview. Ann NY Acad Sci. 931: 1-16.
69. Woerner MG, Mannuzza S, Kane JM. 1988. Anchoring the BPRS: An aid to improved reliability. Psychopharmacol Bull 24: 112-117.
70. Wong DF, Brašić JR. 2001. In vivo imaging of neurotransmitter systems in neuropsychiatry. Clin Neurosci Res 1(1-2): 35-45.
71. Wong DF, Brašić JR. 2005. Progress in the neuropsychiatry of schizophrenia. Psychiatr Times 22(3): 57, 58, 60.
72. Wong DF, Brašić JR, Cascella N. 2011. Neuroreceptor imaging of schizophrenia. In: Shenton ME, Turetsky BI, editors. Understanding neuropsychiatric disorders: Insights from neuroimaging. Cambridge, UK: Cambridge University Press. p 78-87.
73. Wong DF, Broussolle EP, Wand G, Villemagne V, Dannals RF, Links JM, Zacur HA, Harris J, Naidu S, Braestrup C, Wagner HNJr, Gjedde A. 1988. In vivo measurement of dopamine receptors in human brain by positron emission tomography. Age and sex differences. Ann NY Acad Sci 515: 203-214.
74. Wong DF, Gründer G, Brašić JR. 2007. Brain imaging research: Does the science serve clinical practice? Int Rev Psychiatry 19: 541-558.
75. Wong DF, Gründer G, Cascella NG, Brašić JR. 2009. Molecular brain imaging in schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan & Sadock's comprehensive textbook of psychiatry, 9th ed. Chapter 12.9 in Volume 1. Philadelphia: Lippincott Williams & Wilkins. p 1519-1530.
76. Wong DF, Maini A, Rousset OG, Brašić JR. 2003. Positron emission tomography-A tool for identifying the effects of alcohol dependence on the brain. Alcohol Res Health 27: 161-173.
77. Wong DF, Wagner HNJr, Dannals RF, Links JM, Frost JJ, Ravert HT, Wilson AA, Rosenbaum AE, Gjedde A, Douglass KH, Petronis JD, Folstein MF, Toung JKY, Burns HD, Kuhar MJ. 1984. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 226: 1393-1396.
78. Wüllner U, Gündisch D, Herzog H, Minnerop M, Joe A, Warnecke M, Jessen F, Schütz C, Reinhardt M, Eschner W, Klockgether T, Schmaljohann J. 2008. Smoking upregulates α4β2* nicotinic acetylcholine receptors in the human brain. Neurosci Lett 430: 34-37.
79. 123I]5-A-85380 dynamic SPECT studies in normals: kinetic analysis and parametric imaging. Nuclear Science Symposium Conference Record, 2001 Institute of Electrical and Electronics Engineers (IEEE), Incorporated 3: 1335-1340.
80. 123I](S)-5-iodo-3-(2-azetidinylmethoxy)pyridine (5IA) for subjects with Rett syndrome. 3rd Annual Rett Syndrome Symposium, June 17-19, 2002, Inn at The Colonnade, Baltimore, Maryland. Rett Syndrome Research Foundation, Cincinnati, Ohio www.rsrf.org 2002: 31-32 [abstract].
81. Zhou Y, Endres CJ, Dogan AS, Brasic JR, Wong DF, Huang S-C. 2002b. A new linear paramet ric imaging algorithm derived from a simplified reference tissue model for ligand-receptor dynamic PET studies. In: Senda M, Kimura Y, Herscovitch P, editors. Brain Imaging Using PET. Amsterdam: Academic Press. p. 33-39.
82. Zhou Y, Endres CJ, Brašić JR, Huang S-C, Wong DF. 2003. Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. NeuroImage 18: 975-989.
83. th Annual Rett Syndrome Symposium, June 28-30, 2004, Inn at the Colonnade, Baltimore, Maryland, Rett Syndrome Research Foundation (RSRF), Cincinnati, Ohio 2004 page 45 [abstract].